Sato Vicki L's Form 4 filing
Denali Therapeutics Inc.DNLI · filed Sep 4, 2024
- Accession no.
- 0001714899-24-000198
- Filed
- Sep 4, 2024
- Trade date
- Sep 3, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $77.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sato Vicki LCIK 0001197020 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2024 | Common Stock | SSaleDisposed | −2,980 | $24.99F2 | −$74,470.2 | 116,276 | Direct | |
| Sep 3, 2024 | Common Stock | SSaleDisposed | −100 | $25.37 | −$2,537 | 116,176 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.37 to $25.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.